Ependymoma is a central nervous system tumor that occurs primarily in children and can arise in the supratentorial region, posterior fossa, or spinal cord. Although molecular classification has substantially improved disease stratification and prognostic assessment, the metabolic phenotypes associated with the major pediatric subtypes have remained poorly defined. Because pediatric ependymoma is rare, assembling a cohort that spans multiple molecularly defined subtypes for systematic metabolic comparison is itself challenging.

A recent study published in Life Metabolism, led by Prof. Woo-ping Ge at the Beijing Institute for Brain Research, now provides a systematic metabolomic analysis of 42 pediatric ependymomas spanning the four major molecular subtypes: ST-RELA, ST-YAP1, PFA, and PFB. The study identifies subtype-associated metabolic programs and links them to known differences in clinical aggressiveness, providing a resource for understanding the biology of pediatric ependymoma and a foundation for future studies of metabolism-guided therapeutic vulnerability (Figure 1).

Using untargeted metabolomic profiling of tumor tissues, the researchers found that global metabolic patterns were shaped more strongly by molecular subtype than by anatomical location. Briefly, ST-YAP1 showed the most distinct overall metabolic profile, and the largest divergence was observed between the two supratentorial subtypes, ST-RELA and ST-YAP1. By contrast, the two posterior fossa subtypes, PFA and PFB, were metabolically much more similar. These findings suggest that the metabolic organization of pediatric ependymoma is closely coupled to the underlying molecular lesions that define each subtype.

Further analysis showed that the more aggressive ST-RELA subtype was characterized by enrichment of acylcarnitines and increased expression of fatty acid oxidation-related genes, including CPT1A, CPT1C, and CPT2, consistent with a lipid-utilizing metabolic program. In public pediatric brain tumor data, higher CPT1A expression was associated with poorer overall survival in ependymoma. Polyamine metabolites were enriched in both PFA and ST-RELA, the two clinically more aggressive subtypes, and were further increased in younger patients with PFA. By contrast, the favorable-prognosis ST-YAP1 subtype showed markedly lower levels of nucleotides and nucleotide sugars, consistent with a less proliferative and more differentiated state.

Taken together, this study maps the metabolic heterogeneity of pediatric ependymoma to its molecular subtypes. The identified dependencies, fatty acid oxidation in ST-RELA and polyamine metabolism in PFA/ST-RELA, represent promising metabolic vulnerabilities. The study therefore provides a first systematic view of metabolic heterogeneity across the major pediatric ependymoma subtypes.
DOI
10.1093/lifemeta/loag010